  Until recently , the diagnosis of spinal muscular atrophy ( SMA) has been associated with severe life-long motor disability in adults and with early death in infants. The new experimental therapeutic approaches of the last few years have become more and more promising , while nusinersen was approved for the treatment of SMA in December 2016 in the USA , and in May 2017 in Hungary. Our paper presents mechanisms and clinical benefits of this new medication , and highlights some of the other therapeutic strategies still in experimental stages.